Condition: Refractory Acute Myeloid Leukemia · Relapsed Acute Myeloid Leukemia · Acute Leukemia of Ambiguous Lineage · Sponsor: St. Jude Children's Research Hospital
This is a research study to find out if adding a new study drug called revumenib to commonly used chemotherapy drugs is safe and if they have beneficial effects in treating patients with acute myeloid leukemia (AML) or acute leukemia of ambiguous lineage (ALAL) that did not go into remission after treatment (refractory) or has come back after treatment (relapsed), and to determine the total dose of the 3-drug combination of revumenib, azacitidine and venetoclax that can be given safely in participants also taking an anti-fungal drug. Primary Objective * To determine the safety and tolerability of revumenib + azacitidine + venetoclax in pediatric patients with relapsed or refractory AML or ALAL. Secondary Objectives * Describe the rates of complete remission (CR), complete remission with incomplete count recovery (CRi), and overall survival for patients treated with revumenib + azacitidine + venetoclax at the recommended phase 2 dose (RP2D).
This description comes directly from the study's public registry record.
Hiroto Inaba, MD, PhD · 888-226-4343 · referralinfo@stjude.org
Always discuss trial participation with your own doctor first.
| Rady Children's Hospital | San Diego, California, United States | Recruiting |
| Children's Hospital Colorado | Aurora, Colorado, United States | Recruiting |
| Children's Healthcare of Atlanta | Atlanta, Georgia, United States | Recruiting |
| Children's Mercy Hospital of Kansas City | Kansas City, Missouri, United States | Recruiting |
| Memorial Sloan- Kettering Cancer Center | New York, New York, United States | Recruiting |
| Cincinnati Children's Hospital Medical Center | Cincinnati, Ohio, United States | Recruiting |
| Children's Hospital of Philadelphia | Philadelphia, Pennsylvania, United States | Recruiting |
| St. Jude Children's Research Hospital | Memphis, Tennessee, United States | Recruiting |
| UT Southwestern/Simmons Cancer Center | Dallas, Texas, United States | Recruiting |
| Cook Children's Medical Center | Fort Worth, Texas, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06177067